Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | DRD3 | P35462 | 5/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577434 | 0.85 | MAPK1 (0.51) | DRD2DRD3DRD4MAPK1KMT2A | |
| SCHEMBL5577884 | 0.83 | SIGMAR1 (0.47) | DRD2DRD3DRD4ALDH1A1LMNA | |
| SCHEMBL5577639 | 0.82 | LMNA (0.61) | DRD2MAPK1KMT2AMEN1LMNA | |
| SCHEMBL5577456 | 0.81 | KMT2A (0.53) | DRD2DRD3DRD4MAPK1KMT2A | |
| SCHEMBL5577433 | 0.81 | DRD2 (0.53) | DRD2DRD3DRD4MAPK1 | |
| SCHEMBL5577445 | 0.81 | CHRM3 (0.51) | MAPK1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL5577826 | 0.80 | MT-CO2 (0.49) | DRD2DRD3MAPK1KDM4ENPY2R | |
| SCHEMBL5577767 | 0.79 | MAPK1 (0.62) | DRD2DRD3DRD4MAPK1KMT2A | |
| SCHEMBL5577394 | 0.79 | CNR2 (0.49) | DRD2DRD3DRD4MAPK1NPY2R | |
| SCHEMBL5577451 | 0.77 | SIGMAR1 (0.48) | DRD2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | DRD2 4468/4885DRD3 4080/4885DRD4 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.